1.
Kolars, J. C., Schmiedlin-Ren, P., Schuetz, J. D., Fang, C. & Watkins, P. B. Identification of
rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J. Clin. Invest. 90,
1871–1878 (1992).
2.
Kolars, J. C., Watkins, P. B., Merion, R. M. & Awni, W. M. First-pass metabolism of cyclosporin
by the gut. Lancet 338, 1488–1490 (1991).
3.
Strassburg, C. P., Oldhafer, K., Manns, M. P. & Tukey, R. H. Differential expression of the
UGT1A locus in human liver, biliary, and gastric tissue: identification of UGT1A7 and
UGT1A10 transcripts in extrahepatic tissue. Mol. Pharmacol. 52, 212–20 (1997).
4.
Tukey, R. H. & Strassburg, C. P. Human UDP-Glucuronosyltransferases: Metabolism,
Expression, and Disease. Annu. Rev. Pharmacol. Toxicol. 40, 581–616 (2000).
5.
Fisher, M. B., Paine, M. F., Strelevitz, T. J. & Wrighton, S. A. The role of hepatic and
extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab. Rev. 33,
273–297 (2001).
6.
Cheng, Z., Radominska-Pandya, A. & Tephly, T. R. Cloning and Expression of Human
UDP-Glucuronosyltransferase (UGT) 1A8. Arch. Biochem. Biophys. 356, 301–305 (1998).
7.
Mulder, G. J. & Jakoby, W. B. Sulfation in conjugation reactions. In Drug Metab. (Mulder, G. J.
83
& Jakoby, W. B.) 107–161 (Taylor and Francis, London, 1990).
8.
Falany, C. N. & Roth, J. A. Properties of human cytosolic sulfotransferases involved in drug
metabolism. In Hum. drug Metab. from Mol. Biol. to man. (Jeffery, E. H.) 101–115 (CRC Press,
Boca Raton, 1993).
9.
Weinshilboum, R. & Otterness, D. M. Sulfotransferase enzyme conjugation-deconjugation
reactions. In Conjug. React. drug Metab. Toxic. (Kaufman, F. C.) 45–78 (Springer-Verlag, Berlin,
1994).
10.
Thiebaut, F. et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in
normal human tissues. Proc. Natl. Acad. Sci. U. S. A. 84, 7735–7738 (1987).
11.
Saitoh, H. & Aungst, B. J. Possible involvement of multiple P-glycoprotein-mediated efflux
systems in the transport of verapamil and other organic cations across rat intestine. Pharm. Res.
12, 1304–1310 (1995).
12.
Paine, M. F. et al. Characterization of interintestinal and intraintestinal variations in human
CYP3A-dependent metabolism. J. Pharmacol. Exp. Ther. 283, 1552–1562 (1997).
13.
Maliepaard, M. et al. Subcellular localization and distribution of the Breast Resistance Protein
Transporter in normal human tissues. Cancer Res. 61, 3458–3464 (2001).
14.
Doyle, L. A. et al. A multidrug resistance transporter from human MCF-7 breast cancer cells.
Proc. Natl. Acad. Sci. 95, 15665–15670 (1998).
84
15.
Borst, P., Evers, R., Kool, M. & Wijnholds, J. The multidrug resistance protein family. Biochim.
Biophys. Acta - Biomembr. 1461, 347–357 (1999).
16.
König, J., Nies, A. T., Cui, Y., Leier, I. & Keppler, D. Conjugate export pumps of the multidrug
resistance protein (MRP) family: Localization, substrate specificity, and MRP2-mediated drug
resistance. Biochim. Biophys. Acta - Biomembr. 1461, 377–394 (1999).
17.
Paine, M. F. et al. The human intestinal cytochrome P450 ‘pie’. Drug Metab. Dispos. 34,
880–886 (2006).
18.
Guengerich, F. P. Cytochrome P450 and Chemical Toxicology. Chem. Res. Toxicol. 21, 70–83
(2008).
19.
Wacher, V. J., Wu, C. Y. & Benet, L. Z. Overlapping substrate specificities and tissue distribution
of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer
chemotherapy. Mol. Carcinog. 13, 129–34 (1995).
20.
Nakashima, M. et al. Study on Safety, Pharmacodynamics and Pharmacokinetics of Felodipine
Following Single Oral Administration in Healthy Adult Male Volunteers. Rinsyoiyaku 8,
1763–1780 (1992).
21.
Bornemann, L. D. et al. Dose dependent pharmacokinetics of midazolam. Eur. J. Clin.
Pharmacol. 29, 91–95 (1985).
22.
Nichols, D. J., Muirhead, G. J. & Harness, J. A. Pharmacokinetics of sildenafil after single oral
85
doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br.
J. Clin. Pharmacol. 53 Suppl 1, 5S-12S (2002).
23.
Nakashima, M., Kanemaru, M., Takiguchi, Y. & Mizuno, A. Phase I Study of NBP-582
(Celiprolol). Rinsyoiyaku 4, 1075–1090 (1988).
24.
Wetterich, U. et al. Evidence for intestinal secretion as an additional clearance pathway of
talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo. Pharm.
Res. 13, 514–522 (1996).
25.
Yeh, K. C. et al. Single-dose pharmacokinetics of indinavir and the effect of food. Antimicrob.
Agents Chemother. 42, 332–338 (1998).
26.
Abuasal, B. S., Bolger, M. B., Walker, D. K. & Kaddoumi, A. In silico modeling for the
nonlinear absorption kinetics of UK-343,664: a P-gp and CYP3A4 substrate. Mol. Pharm. 9,
492–504 (2012).
27.
Artursson, P. & Karlsson, J. Correlation between oral drug absorption in humans and apparent
drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys.
Res. Commun. 175, 880–885 (1991).
28.
Yang, J., Jamei, M., Yeo, K. R., Tucker, G. T. & Rostami-Hodjegan, A. Prediction of intestinal
first-pass drug metabolism. Curr. Drug Metab. 8, 676–684 (2007).
29.
Agoram, B. & Woltosz, W. Predicting the impact of physiological and biochemical processes on
86
oral drug bioavailability. Adv. Drug Deliv. Rev. 50, S41–S67 (2001).
30.
Venkatakrishnan, K. et al. Comparison between cytochrome P450 (CYP) content and relative
activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of
accessory proteins as sources of discrepancies between the approaches. Drug Metab. Dispos. 28,
1493–1504 (2000).
31.
Taguchi, M. et al. Kinetics of testosterone 6beta-hydroxylation in the reconstituted system with
similar ratios of purified CYP3A4, NADPH-cytochrome p450 oxidoreductase and cytochrome B5
to human liver microsomes. Res. Commun. Mol. Pathol. Pharmacol. 109, 53–63 (2001).
32.
Kudo, T. et al. Effect of buffer conditions on CYP2C8-mediated paclitaxel 6α-hydroxylation and
CYP3A4-mediated triazolam α- and 4-hydroxylation by human liver microsomes. Xenobiotica.
46, 241–246 (2016).
33.
Tachibana, T., Kato, M., Watanabe, T., Mitsui, T. & Sugiyama, Y. Method for predicting the risk
of drug-drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein.
Xenobiotica. 39, 430–443 (2009).
34.
Petri, N., Tannergren, C., Rungstad, D. & Lennernäs, H. Transport Characteristics of
Fexofenadine in the Caco-2 Cell Model. Transport 21, 1398–1404 (2004).
35.
Yamazaki, A. et al. Microdose study of a P-glycoprotein substrate, fexofenadine, using a
non-radioisotope-labelled drug and LC/MS/MS. J. Clin. Pharm. Ther. 35, 169–175 (2010).
87
36.
Shirasaka, Y., Sakane, T. & Yamashita, S. Effect of P-glycoprotein expression levels on the
concentration-dependent permeability of drugs to the cell membrane. J. Pharm. Sci. 97, 553–565
(2008).
37.
Obach, R. S. & Reed-Hagen, A. E. Measurement of Michaelis constants for cytochrome
P450-mediated biotransformation reactions using a substrate depletion approach. Drug Metab.
Dispos. 30, 831–837 (2002).
38.
Yamaoka, K., Tanigawara, Y., Nakagawa, T. & Uno, T. A pharmacokinetic analysis program
(multi) for microcomputer. J. Pharmacobiodyn. 4, 879–885 (1981).
39.
Ito, K. et al. Prediction of pharmacokinetic alterations caused by drug-drug interactions:
metabolic interaction in the liver. Pharmacol. Rev. 50, 387–412 (1998).
40.
Sawada, Y., Hanano, M., Sugiyama, Y., Harashima, H. & Iga, T. Prediction of the volumes of
distribution of basic drugs in humans based on data from animals. J. Pharmacokinet. Biopharm.
12, 587–596 (1984).
41.
Manitpisitkul, P. & Chiou, W. L. Intravenous verapamil kinetics in rats: Marked arteriovenous
concentration difference and comparison with humans. Biopharm. Drug Dispos. 14, 555–566
(1993).
42.
Ueda, C. T., Williamson, B. J. & Dzindzio, B. S. Absolute quinidine bioavailability. Clin.
Pharmacol. Ther. 20, 260–265 (1976).
88
43.
Fromm, M. F., Busse, D., Kroemer, H. K. & Eichelbaum, M. Differential induction of prehepatic
and hepatic metabolism of verapamil by rifampin. Hepatology 24, 796–801 (1996).
44.
Dedrick, R. L. & Forrester, D. D. Blood flow limitations in interpreting Michaelis constants for
ethanol oxidation in vivo. Biochem. Pharmacol. 22, 1133–1140 (1973).
45.
Hirota, N. et al. In vitro/in vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in
humans. Biopharm. Drug Dispos. 22, 53–71 (2001).
46.
Naritomi, Y. et al. Prediction of human hepatic clearance from in vivo animal experiments and in
vitro metabolic studies with liver microsomes from animals and humans. Drug Metab. Dispos. 29,
1316–1324 (2001).
47.
Galetin, A., Brown, C., Hallifax, D., Ito, K. & Houston, J. B. Utility of recombinant enzyme
kinetics in prediction of human clearance: impact of variability, CYP3A5, and CYP2C19 on
CYP3A4 probe substrates. Drug Metab. Dispos. 32, 1411–1420 (2004).
48.
Watanabe, T., Kusuhara, H., Maeda, K. & Shitara, Y. Physiologically Based Pharmacokinetic
Modeling to Predict Transporter-Mediated Clearance and Distribution of Pravastatin in Humans.
Pharmacology 328, 652–662 (2009).
49.
Tachibana, T. et al. Model analysis of the concentration-dependent permeability of P-gp
substrates. Pharm. Res. 27, 442–446 (2010).
50.
杉山雄一 & 前田和哉 In vitro-in vivo補外法. In 分子薬物動態学 (杉山雄一 & 楠原洋之)
89
220–247 (南山堂, 東京, 2008).
51.
52.
Interview form of Triazolam. 9th ed. (2012). Fukui, Japan: Kobayashi Kako co., Ltd.
Gramatté, T., Oertel, R., Terhaag, B. & Kirch, W. Direct demonstration of small intestinal
secretion and site-dependent absorption of the beta-blocker talinolol in humans. Clin. Pharmacol.
Ther. 59, 541–549 (1996).
53.
Bergström, C. A. S., Luthman, K. & Artursson, P. Accuracy of calculated pH-dependent aqueous
drug solubility. Eur. J. Pharm. Sci. 22, 387–398 (2004).
54.
Wynne, H. A. et al. The effect of age upon liver volume and apparent liver blood flow in healthy
man. Hepatology 9, 297–301 (1989).
55.
Bengtsson-Hasselgren, B., Rönn, O., Blychert, L. O., Edgar, B. & Raner, S. Acute effects of
felodipine and nifedipine on hepatic and forearm blood flow in healthy men. Eur. J. Clin.
Pharmacol. 38, 529–533 (1990).
56.
Greenblatt, D. J. et al. Ketoconazole inhibition of triazolam and alprazolam clearance:
Differential kinetic and dynamic consequences. Clin. Pharmacol. Ther. 64, 237–247 (1998).
57.
Greenblatt, D. J. et al. Inhibition of triazolam clearance by macrolide antimicrobial agents: in
vitro correlates and dynamic consequences. Clin. Pharmacol. Ther. 64, 278–285 (1998).
58.
Caruso, F. S. et al. Celiprolol: pharmacokinetics and duration of pharmacodynamic activity. Br. J.
Clin. Pract. Suppl. 40, 12–16 (1985).
90
59.
Lappin, G. et al. Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of
absolute oral bioavailability. Eur. J. Pharm. Sci. 40, 125–131 (2010).
60.
Sun, D. et al. Comparison of human duodenum and Caco-2 gene expression profiles for 12,000
gene sequences tags and correlation with permeability of 26 drugs. Pharm. Res. 19, 1400–1416
(2002).
61.
Lin, Y. S. et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal
midazolam metabolism. Mol. Pharmacol. 62, 162–172 (2002).
62.
Haufroid, V. et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine
and tacrolimus dose requirements and trough blood levels in stable renal transplant patients.
Pharmacogenetics 14, 147–154 (2004).
63.
Mai, I. et al. MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state
pharmacokinetics of tacrolimus in renal transplant patients. Br. J. Clin. Pharmacol. 58, 548–553
(2004).
64.
Dresser, G. et al. Fruit juices inhibit organic anion transporting polypeptide–mediated drug
uptake to decrease the oral availability of fexofenadine. Clin. Pharmacol. Ther. 71, 11–20 (2002).
65.
Kato, Y. et al. Involvement of Influx and Efflux Transport Systems in Gastrointestinal
Absorption of Celiprolol. Animals 98, 2529–2539 (2009).
66.
Schwarz, U. I. et al. Grapefruit juice ingestion significantly reduces talinolol bioavailability. Clin.
91
Pharmacol. Ther. 77, 291–301 (2005).
67.
Mouly, S. & Paine, M. F. P-Glycoprotein Increases from Proximal to Distal Regions of Human
Small Intestine. October 20, 1595–1599 (2003).
68.
Sheiner, L. B. & Beal, S. L. Some suggestions for measuring predictive performance. J.
Pharmacokinet. Biopharm. 9, 503–512 (1981).
69.
Obach, R. S. et al. The prediction of human pharmacokinetic parameters from preclinical and in
vitro metabolism data. J. Pharmacol. Exp. Ther. 283, 46–58 (1997).
70.
Gertz, M., Houston, J. B. & Galetin, A. Physiologically based pharmacokinetic modeling of
intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction. Drug Metab.
Dispos. 39, 1633–1642 (2011).
71.
Holmstock, N. et al. Exploring food effects on indinavir absorption with human intestinal fluids
in the mouse intestine. Eur. J. Pharm. Sci. 49, 27–32 (2013).
72.
Yeh, K. C. et al. Simultaneous investigation of indinavir nonlinear pharmacokinetics and
bioavailability in healthy volunteers using stable isotope labeling technique: study design and
model-independent data analysis. J. Pharm. Sci. 88, 568–573 (1999).
73.
Kawai, Y. et al. Profiling and trend analysis of food effects on oral drug absorption considering
micelle interaction and solubilization by bile micelles. Drug Metab. Pharmacokinet. 26, 180–191
(2011).
92
74.
Maeda, K. et al. Nonlinear pharmacokinetics of oral quinidine and verapamil in healthy subjects:
a clinical microdosing study. Clin. Pharmacol. Ther. 90, 263–270 (2011).
75.
Ke, A. B., Nallani, S. C., Zhao, P., Rostami-Hodjegan, A. & Unadkat, J. D. A PBPK Model to
Predict Disposition of CYP3A-Metabolized Drugs in Pregnant Women: Verification and
Discerning the Site of CYP3A Induction. CPT pharmacometrics Syst. Pharmacol. 1, 1–10 (2012).
76.
Kato, Y. et al. Involvement of influx and efflux transport systems in gastrointestinal absorption of
celiprolol. J. Pharm. Sci. 98, 2529–2539 (2009).
77.
Englund, G. et al. Regional levels of drug transporters along the human intestinal tract:
Co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur. J. Pharm.
Sci. 29, 269–277 (2006).
78.
Uchimura, T., Kato, M., Saito, T. & Kinoshita, H. Prediction of human blood-to-plasma drug
concentration ratio. Biopharm. Drug Dispos. 31, 286–297 (2010).
79.
Edgar, B. et al. Felodipine kinetics in healthy men. Clin. Pharmacol. Ther. 38, 205–211 (1985).
80.
Tsunoda, S. M., Velez, R. L., Moltke, L. L. von & Greenblatt, D. J. Differentiation of intestinal
and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of
ketoconazole. Clin. Pharmacol. Ther. 66, 461–471 (1999).
81.
Perdaems, N. et al. Predictions of metabolic drug-drug interactions using physiologically based
modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil.
93
Clin. Pharmacokinet. 49, 239–258 (2010).
82.
Gertz, M., Harrison, A., Houston, J. B. & Galetin, A. Prediction of human intestinal first-pass
metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab.
Dispos. 38, 1147–1158 (2010).
83.
Vanderveen, R. P., Jirak, J. L., Peters, G. R., Cox, S. R. & Bombardt, P. A. Effect of ranitidine on
the disposition of orally and intravenously administered triazolam. Clin. Pharm. 10, 539–543
(1991).
84.
Kroboth, P. D., McAuley, J. W., Kroboth, F. J., Bertz, R. J. & Smith, R. B. Triazolam
pharmacokinetics after intravenous, oral, and sublingual administration. J. Clin.
Psychopharmacol. 15, 259–262 (1995).
85.
Goodman, L. S., Gilman, A., Hardman, J. G., Gilman, A. G. & Limbird., L. E. Goodman and
Gilmans’s the pharmacological basis of therapeutics. 11th ed. New York. (2005).
86.
Hughes, I. E., Ilett, K. F. & Jellett, L. B. The distribution of quinidine in human blood. Br. J. Clin.
Pharmacol. 2, 521–525 (1975).
87.
Kupferschmidt, H. H., Fattinger, K. E., Ha, H. R., Follath, F. & Krähenbühl, S. Grapefruit juice
enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br. J. Clin.
Pharmacol. 45, 355–359 (1998).
88.
Fromm, M., Busse, D. & Kroemer, H. Differential induction of prehepatic and hepatic
94
metabolism of verapamil by rifampin. Hepatology 24, 796–801 (1996).
89.
Rostami-Hodjegan, A. & Tucker, G. T. Simulation and prediction of in vivo drug metabolism in
human populations from in vitro data. Nat. Rev. Drug Discov. 6, 140–148 (2007).
90.
Gerecke, M. Chemical structure and properties of midazolam compared with other
benzodiazepines. Br. J. Clin. Pharmacol. 16 Suppl 1, 11S-16S (1983).
91.
Rodgers, T. & Rowland, M. Mechanistic approaches to volume of distribution predictions:
understanding the processes. Pharm. Res. 24, 918–933 (2007).
92.
Grube, S. et al. Biowaiver monographs for immediate release solid oral dosage forms: quinidine
sulfate. J. Pharm. Sci. 98, 2238–2251 (2009).
93.
Winiwarter, S. et al. Correlation of human jejunal permeability (in vivo) of drugs with
experimentally and theoretically derived parameters. A multivariate data analysis approach. J.
Med. Chem. 41, 4939–4949 (1998).
94.
Damkier, P., Hansen, L. L. & Brøsen, K. Effect of fluvoxamine on the pharmacokinetics of
quinidine. Eur. J. Clin. Pharmacol. 55, 451–456 (1999).
95.
Darbar, D., Dell’Orto, S., Mörike, K., Wilkinson, G. R. & Roden, D. M. Dietary salt increases
first-pass elimination of oral quinidine. Clin. Pharmacol. Ther. 61, 292–300 (1997).
96.
Hsu, A. et al. Pharmacokinetic interactions between two human immunodeficiency virus protease
inhibitors, ritonavir and saquinavir. Clin. Pharmacol. Ther. 63, 453–464 (1998).
95
97.
Mizuma, T. Intestinal glucuronidation metabolism may have a greater impact on oral
bioavailability than hepatic glucuronidation metabolism in humans: A study with raloxifene,
substrate for UGT1A1, 1A8, 1A9, and 1A10. Int. J. Pharm. 378, 140–141 (2009).
98.
Kemp, D. C., Fan, P. W. & Stevens, J. C. Characterization of raloxifene glucuronidation in vitro:
Contribution of intestinal metabolism to presystemic clearance. Drug Metab. Dispos. 30, 694–700
(2002).
99.
Kuppens, I. E. L. M. et al. A phase I, randomized, open-label, parallel-cohort, dose-finding study
of elacridar (GF120918) and oral topotecan in cancer patients. Clin. Cancer Res. 13, 3276–3285
(2007).
96
謝辞
本研究の推進にあたり、終始御懇篤なる御指導、御鞭撻を賜りました東京大学大学院 薬学系
研究科 分子薬物動態学教室 教授 楠原洋之 先生、並びに国立研究開発法人理化学研究所 科技
ハブ産連本部 バトンゾーン研究推進プログラム 杉山特別研究室 杉山雄一 先生に深謝いたし
ます。
本研究の遂行にあたり、多大なる御助言と御指導を賜りました東京大学大学院薬学系研究科分
子薬物動態学教室 講師 前田和哉 先生に深謝いたします。
臨床研究の実施、並びに臨床サンプルの提供に際しご尽力いただきました、北里大学病院 臨
床試験センター長 熊谷雄治 先生に深謝いたします。
解析ソフトウェアの提供に際しご尽力いただきました、ノーザンサイエンスコンサルティング
株式会社 東嶋 知彦 氏に深謝いたします。
本研究の機会を与えてくださり、研究の推進に多大なるご支援を賜りました杏林製薬株式会社
薬物動態研究所長 鳥海千冬 博士に深謝いたします。
97
最後に私の研究を支えてくださいました、東京大学大学院 薬学系研究科 分子薬物動態学教室
の皆さま、杏林製薬株式会社 薬物動態研究所の皆さま、そして私の家族に深く感謝いたします。
98
...
論文の公開元へ
